Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:CLGN

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

CollPlant Biotechnologies logo
$3.66 +0.04 (+1.10%)
As of 12:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

Advanced

Key Stats

Today's Range
$3.52
▼
$3.66
50-Day Range
$2.90
▼
$4.56
52-Week Range
$2.64
▼
$23.80
Volume
7,734 shs
Average Volume
119,157 shs
Market Capitalization
$6.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00
Consensus Rating
Reduce

Company Overview

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an Israel-based biotechnology company developing regenerative medicine products and tissue-engineering technologies. The company’s platform uses genetically engineered tobacco plants to produce recombinant human collagen (rhCollagen), a purified collagen material designed to support the repair, replacement, and regeneration of human tissue.

CollPlant develops rhCollagen-based products for applications including 3D bioprinting, tissue engineering, and advanced wound care. Its technologies are intended for use in bioinks, scaffolds, and other medical products, with research focused particularly on soft-tissue reconstruction and implantable regenerative solutions. The company has also pursued collaborations with medical technology and bioprinting companies to develop next-generation human tissue and organ-replacement products.

CollPlant traces its origins to 2004 and is headquartered in Rehovot, Israel. Its business is internationally oriented, with research, development, and commercial collaboration activities involving partners and potential customers in multiple global markets. The company is led by Chief Executive Officer Yehiel Tal.

AI Generated. May Contain Errors.

CollPlant Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

CLGN MarketRank™: 
2.089442815245 of 5 stars

CollPlant Biotechnologies scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CollPlant Biotechnologies has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    CollPlant Biotechnologies has a consensus price target of $120.00, representing about 3,214.9% upside from its current price of $3.62.

  • Amount of Analyst Coverage

    CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about CollPlant Biotechnologies' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CollPlant Biotechnologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CollPlant Biotechnologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CollPlant Biotechnologies has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about CollPlant Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    2.47% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.54, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently decreased by 19.17%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CollPlant Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    CollPlant Biotechnologies does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for CollPlant Biotechnologies this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for CLGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.60% of the stock of CollPlant Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    21.69% of the stock of CollPlant Biotechnologies is held by institutions.

  • Read more about CollPlant Biotechnologies' insider trading history.
Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLGN Stock News Headlines

LightSolver and Why AI May Outrun the GPU (NASDAQ: CLGN)
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
CollPlant Biotechnologies Q2 Net Loss Narrows
See More Headlines

CLGN Stock Analysis - Frequently Asked Questions

CollPlant Biotechnologies' stock was trading at $14.00 at the start of the year. Since then, CLGN stock has decreased by 74.1% and is now trading at $3.62.

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) released its earnings results on Wednesday, September, 30th. The company reported ($1.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.45) by $0.56. The business earned $0.11 million during the quarter, compared to analyst estimates of $0.48 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 298.21% and a negative net margin of 678.37%.

CollPlant Biotechnologies's stock reverse split before market open on Friday, September 4th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SoFi Technologies (SOFI), Tesla (TSLA), ChargePoint (CHPT), Ford Motor (F) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
9/30/2026
Today
10/23/2026
Next Earnings (Estimated)
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLGN
CIK
1631487
Employees
39
Year Founded
1981

Price Target and Rating

High Price Target
$120.00
Low Price Target
$120.00
Potential Upside/Downside
+3,178.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($13.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.49 million
Net Margins
-678.37%
Pretax Margin
-490.32%
Return on Equity
-298.21%
Return on Assets
-167.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.57
Quick Ratio
1.35

Sales & Book Value

Annual Sales
$2.37 million
Price / Sales
2.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.76 per share
Price / Book
0.77

Miscellaneous

Outstanding Shares
1,890,000
Free Float
1,709,000
Market Cap
$6.92 million
Optionable
Optionable
Beta
1.77

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:CLGN) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners